Weaknesses
* The weaknesses of the pharmaceutical industry’s SWOT analysis document the internal industry components that are not providing significant added value or are in need of improvement. The internal industry components can include physical resources, human capital or features the industry can control. For example, the pharmaceutical industry’s weaknesses could include high-risk business modeling, disengaged Board of Directors, dated medical equipment, poor branding, low staff morale or diseconomies of scale. * Sponsored Links * Contract Pharma Magazine
Read this Months Issue - For Pharma Biopharma Outsourcing Professionals www.contractpharma.com Opportunities * The opportunities of the pharmaceutical industry’s SWOT analysis document the external industry components that provide a chance for the industry (or factions of the industry) to grow in some capacity or gain a competitive edge. The external industry components should be environmental factors or aspects outside the industry’s control, yet reflective of the business marketplace. For example, the pharmaceutical industry’s opportunities could include recently published research, an increase in health-conscious consumers, increased demand for pharmaceutical products, changes in Food and